In an article published by Bloomberg Law, Partners Barish Ozdamar and Omar Khan, Senior Associate Amy Mahan and Associate Iva Dincheva examine the enablement of AI inventions and the questions that come up after Amgen regarding the evolving nature of AI models.
Excerpt: “Personalized medical intervention is in a transformative phase as artificial intelligence algorithms are increasingly deployed to tailor treatments for individual patients based on their unique characteristics.
Developers face the task of adequately protecting AI-based technologies under current US patent jurisprudence. Enablement and necessary disclosures to obtain patents related to AI are one such challenge.”
